Neuropituitary Hormones in Metabolic Disorders
A special issue of Current Issues in Molecular Biology (ISSN 1467-3045). This special issue belongs to the section "Biochemistry, Molecular and Cellular Biology".
Deadline for manuscript submissions: 31 May 2026 | Viewed by 2931
Special Issue Editor
Interests: oxytocin; thermoregulation; skeletal muscle; obesity; Prader–Willi syndrome
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Oxytocin and vasopressin are highly conserved 9-amino acid neuropeptides differing by only two amino acids. Oxytocin and vasopressin are produced in overlapping regions of the supraoptic and paraventricular nuclei of the hypothalamus and secreted by parvocellular neurons directly into multiple brain regions that simultaneously project both to forebrain regions and to the posterior pituitary gland, where they are stored until release to the peripheral circulation. Oxytocin receptors and vasopressin receptors are structurally similar, and both neuropeptides can bind to both receptors but with different affinities. Oxytocin is known for its effects of uterus contractility and lactation while vasopressin has antidiuretic action on the kidney and mediates vasoconstriction of the peripheral vessels. Overall, oxytocin and vasopressin exert central and peripheral effects that can be distinct, opposing, or complementary. However, about 20 years ago, genetic knockout mice lacking oxytocin or oxytocin receptor genes shed new light on the physiological functions of the oxytocinergic system. Mice lacking oxytocin developed late-onset obesity, abnormal thermoregulation, metabolic syndrome, and sarcopenia despite normal food consumption and a low sympathetic tone. These discoveries established that beyond the classical role of oxytocin in parturition and lactation oxytocin has a wide range of physiological functions and oxytocin-deficiency contributes to clinical morbidity. Oxytocin-deficiency causes a series of diseases and this sets the foundation for human research studies aimed at understanding these diseases and the potential of pharmacological treatment with oxytocin. Indeed, some symptoms described in animal models lacking oxytocin resemble the clinical phenotype of patients with hypothalamic pituitary damage supporting recognition of “oxytocin-deficiency as a new clinical condition”. Moreover, an oxytocin-deficient state has been identified in individuals with vasopressin deficiency, and oxytocin administration is currently under investigation for the treatment of central diabetes insipidus. Recent clinical research has focused on the effects of oxytocin administration in clinical conditions such as obesity and diabetes mellitus, sarcopenia and muscle maintenance, autism spectrum disorder, anorexia nervosa, anxiety, and hypothalamic diseases such as Prader–Willi syndrome, as well as in individuals with hypopituitarism due to brain tumours located in the hypothalamic and pituitary regions, such as craniopharyngioma. The aim of this Special Issue is to collect original research articles and review articles that explain and summarize current knowledge on the oxytocin and vasopressin system and new disorders related to oxytocin deficiency and vasopressin deficiency, together with diagnostic challenges and therapeutic avenues to advance the field.
Dr. Claudia Camerino
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Issues in Molecular Biology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- oxytocin
- vasopressin
- thermoregulation
- obesity
- Prader–Willi syndrome
- autism spectrum disorder
- anorexia nervosa
- craniopharyngioma
- metabolic disorders
- hypothalamic pituitary disorders
- oxytocin-deficiency
- vasopressin-deficiency
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
